Can you create a comprehensive Residency In-Training Examination (RITE) reviewer for internal medicine covering Gastroenterology, Rheumatology, Neurology, and Allergology in a table format?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Comprehensive RITE Reviewer for Internal Medicine

I. GASTROENTEROLOGY

Topic Key High-Yield Points Clinical Pearls
Upper GI Bleeding - Non-Variceal • Peptic ulcer disease accounts for 35-50% of cases [1]
• Mortality: 11% if admitted for bleeding, 33% if develops in-hospital [1]
• Rebleeding definition: Fresh hematemesis/melena + shock (HR >100, SBP <100) OR CVP drop >5mmHg OR Hgb drop >20g/L over 24h [1]
• Hematemesis + melena = more severe bleeding than melena alone [1]
• Haemochezia can indicate massive UGIB [1]
• Always confirm rebleeding endoscopically [1]
UGIB Management • Endoscopy timing: Most patients safe for morning elective list; minority need emergency "out of hours" [1]
• PPI infusion standard for high-risk lesions
• Combined medical-surgical care essential [1]
• Mortality lower in specialist units due to protocol adherence, not technical advances [1]
• 80% have identifiable cause [1]
• Coffee ground emesis = altered black blood [1]
Anticoagulation in GI Bleeding • Warfarin: Give 4-factor PCC + low-dose vitamin K for life-threatening bleeding with INR >2.5 [2]
• DON'T delay endoscopy until INR normalizes [2]
• DOACs: Withhold to facilitate hemostasis; idarucizumab for dabigatran life-threatening bleeding [2]
• Activated charcoal if DOAC taken within 3 hours [2]
• NO vitamin K for DOAC bleeding [2]
• NO bridging therapy for DOACs [2]
• Avoid high-dose vitamin K (>5mg) in high thromboembolic risk [2]
DAPT in GI Bleeding • NEVER withhold both antiplatelet agents - high stent thrombosis risk [2]
• On PPI infusion: Continue aspirin, withhold clopidogrel [2]
• Resume P2Y12 inhibitor within 5 days post-hemostasis for drug-eluting stents [2]
• New generation DES and bare metal stents have similar thrombotic risk [2]
• Highest risk first 6 weeks post-PCI [2]
Irritable Bowel Syndrome - Diarrhea (IBS-D) • First-line: Rifaximin for global symptom improvement [3]
• TCAs: Effective for abdominal pain and global symptoms
• Eluxadoline: For patients without gallbladder (sphincter of Oddi dysfunction risk)
• Alosetron: Restricted use, severe constipation/ischemic colitis risk
• Exclude organic causes before IBS diagnosis [4]
• SSRIs less effective than TCAs [3]
• Antispasmodics provide short-term relief
• Loperamide for diarrhea but not global symptoms [3]
Post-Surgical GI Complications • Anastomotic stricture: Endoscopic dilation first-line; triamcinolone/needle knife for recurrent [4]
• Acid reflux: PPIs ± prokinetics up to 6 weeks [4]
• Bile reflux: Oral sucralfate suspension [4]
• Steatorrhea: Consider PEI, SIBO, severe BAD - test and treat specifically [4]
• Postprandial pain often from eating too much at once [4]
• Don't attribute to IBS until comprehensive workup complete [4]
• History of pre-surgery symptoms critical [4]
Low Anterior Resection Syndrome (LARS) • Assess risk with formal scoring tool pre-surgery [4]
• Offer supported self-management to all patients [4]
• If symptoms persist >3 months: Refer to specialist [4]
• Exclude BAD, PEI, SIBO as worsening factors [4]
• No objective testing required for diagnosis [4]
• Pelvic floor exercises improve outcomes [4]
• Bulking agents reduce clustering [4]
• Transanal irrigation helpful [4]

II. RHEUMATOLOGY

Topic Key High-Yield Points Clinical Pearls
Behçet's Disease - Arthritis/Arthralgia • First-line: Colchicine (increase dose gradually to minimize GI side effects) [5]
• Second-line: IM depot or short-course low-dose oral corticosteroids [5]
• Refractory: Azathioprine or anti-TNF therapy [5]
• Consider: Apremilast, methotrexate, MMF, secukinumab (≥6 years) [5]
• NSAIDs alternative to steroids if no contraindication [6]
• Intra-articular steroids for mono/oligoarticular synovitis [5]
• Caution with MTX: Can worsen extensive mouth ulceration [6]
• Refer to PT/OT/podiatry as needed [5]
Behçet's Disease - Gastrointestinal • Acute flares: Oral/IV corticosteroids first-line [5]
• Mild-moderate: 5-ASA for aphthous/superficial ulcers [5]
• Moderate-severe OR large/deep ulcers: Azathioprine or 6-MP to prevent perforation/bleeding/obstruction [5]
• Severe OR large/deep ulcers: Consider anti-TNF early as first-line [5]
• Taper steroids 7-10 days after clinical remission [5]
• Flares common during/after steroid taper [5]
• Start tapering steroids when starting 5-ASA/AZA/6-MP [6]
• Anti-TNF dose escalation/interval reduction for resistant cases [5]
Behçet's GI - Surgery & Post-Op • Emergency surgery: Life-saving for uncontrolled bleeding, perforation, obstruction [5]
• Post-resection prophylaxis: AZA or 6-MP first-line [5]
• Consecutive resections: Systemic steroids + anti-TNF + AZA to prevent pathergy-like relapse [5]
• Concomitant immunomodulators (AZA/6-MP) with anti-TNF achieve early sustained response [6]
• Consider IBD therapies (JAK inhibitors, ustekinumab, vedolizumab) if refractory [5]
• Continue treatment ≥2 years after endoscopic remission [5]
JAK-STAT GOF Inborn Errors • JAK inhibitors: Promising targeted treatment for JAK-STAT gain-of-function IEI [7]
• Requires comprehensive pretreatment workup and monitoring [7]
• Can serve as bridge to HSCT [7]
• Implementation barriers: Cost, limited access to monitoring [7]
• Standardized protocols needed globally [7]
• Adapt to local healthcare infrastructure [7]

III. NEUROLOGY

Topic Key High-Yield Points Clinical Pearls
Neurologic Manifestations in Systemic Disease • Behçet's can cause sight-threatening eye disease requiring oral/IV corticosteroids first-line [6] • Multidisciplinary approach essential for complex cases
• Early recognition prevents irreversible damage
Post-Transplant Neurologic Complications • After HSCT: GI toxicity predicts post-transplant complications [4]
• Multidisciplinary care includes neurology input for symptom control [4]
• Cytomegalovirus can cause neurologic manifestations post-HSCT [4]
• Early specialist involvement improves outcomes

IV. ALLERGOLOGY/IMMUNOLOGY

Topic Key High-Yield Points Clinical Pearls
Hematopoietic Stem Cell Transplant - GI/Immune • GI toxicity predicts post-transplant complications [4]
• Multidisciplinary approach: Hematology, dietitian, gastroenterology, symptom control [4]
• Diagnostic workup: Endoscopy with small bowel aspirate/biopsies for diarrhea [4]
• Differentiate: SIBO, fungal overgrowth, C. diff, CMV, GvHD [4]
• Upper endoscopy + sigmoidoscopy safer than colonoscopy with similar diagnostic yield [4]
• Wireless capsule NOT recommended for GvHD diagnosis [4]
• Don't delay treatment for typical GvHD while awaiting biopsy [4]
Neuroendocrine Neoplasms (NENs) • Most GI symptoms NOT from hormone excess [4]
• Gastroenterologists should be in NEN MDT [4]
• Surgery and systemic treatments (especially somatostatin analogues) frequently cause GI symptoms [4]
• Comprehensive symptom assessment needed
• Don't assume all symptoms are hormone-related
• Multidisciplinary management essential
Drug Hypersensitivity in Rheumatologic Disease • Thalidomide for refractory GI Behçet's: Last resort only [6]
• Mandatory: Neurophysiology monitoring + contraception counseling for both sexes [6]
• Can combine with anti-TNF for better outcomes [6]
• High teratogenicity risk requires strict protocols
• Peripheral neuropathy monitoring essential
• Consider all IBD treatment options before thalidomide [5]

V. CROSS-CUTTING CONCEPTS FOR RITE SUCCESS

Category Essential Knowledge
Evidence Grading • Grade A: RCTs/systematic reviews
• Grade B: Non-randomized cohorts, case series
• Grade C: Expert opinion, physiology-based [1]
Anticoagulation Bridging • High risk: CHADS-VASc >5, metallic mitral valve, prosthetic valve + AF, <3 months post-VTE, severe thrombophilia [2]
• Low risk: NO bridging recommended [2]
Common RITE Pitfalls • Crystalline arthritis and osteoarthritis: Often tested despite perceived "ease" [8]
• Rheumatology knowledge gaps common across all PGY levels [9]
• GI physical exam frequently inadequate (58.6% "needs improvement") [10]
Test-Taking Strategy • ITE scores improve predictably with each training year [11]
• IMGs consistently outperform US grads since 1995 [11]
• Timing and available time affect performance [11]

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.